

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.		
10/046,540	01/16/2002	Gavriel J. Iddan	P-2752-US	1800		
49443 7	590 01/19/2006		EXAM	INER		
PEARL COH	PEARL COHEN ZEDEK, LLP			FOREMAN, JONATHAN M		
10 ROCKEFE	LLER PLAZA		ART UNIT	PAPER NUMBER		
SUITE 1001			ARTUNIT	PAPER NUMBER		
NEW YORK,	NY 10020		3736			

DATE MAILED: 01/19/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

		Α	pplication No.	Applicant(s)				
. Office Action Summary		1	0/046,540	IDDAN, GAVRIEL	J			
		Ē	xaminer	Art Unit				
			onathan ML Foreman	3736				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply								
WHIC - Exter after - If NO - Failu	CORTENED STATUTORY PERIOD F HEVER IS LONGER, FROM THE M Isions of time may be available under the provisions SIX (6) MONTHS from the mailing date of this come period for reply is specified above, the maximum single to reply within the set or extended period for reply eply received by the Office later than three months and patent term adjustment. See 37 CFR 1.704(b).	MAILING DATE s of 37 CFR 1.136(a) munication. latutory period will al y will, by statute, cau	E OF THIS COMMUNICA In no event, however, may a reply pply and will expire SIX (6) MONTH se the application to become ABAN	TION. be timely filed from the mailing date of this of the control of the contr				
Status								
1)[🛛	Responsive to communication(s) file	ed on <u>17 Nove</u>	ember <u>2005</u> .					
	This action is FINAL. 2b) This action is non-final.							
3) 🗌	Since this application is in condition for allowance except for formal matters, prosecution as to the ments is							
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.							
Dispositi	on of Claims							
4)⊠	4) Claim(s) 72-76 is/are pending in the application.							
	4a) Of the above claim(s) is/are withdrawn from consideration.							
5)	Claim(s) is/are allowed.							
6)⊠	Claim(s) <u>72-76</u> is/are rejected.							
7)	Claim(s) is/are objected to.	11						
8)[_]	Claim(s) are subject to restri	ction and/or ei	ection requirement.					
Applicati	on Papers							
9)	The specification is objected to by th	ne Examiner.						
10) The drawing(s) filed on is/are: a) □ accepted or b) □ objected to by the Examiner.								
	Applicant may not request that any obje							
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.								
11)	The oath or declaration is objected t	o by the Exam	liner. Note the attached C	onice Action of form P	10-152.			
Priority (ınder 35 U.S.C. § 119							
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:								
	1. Certified copies of the priority documents have been received.							
	2. Certified copies of the priority documents have been received in Application No							
	3. Copies of the certified copies of the priority documents have been received in this National Stage							
application from the International Bureau (PCT Rule 17.2(a)).								
* See the attached detailed Office action for a list of the certified copies not received.								
Attachmen	tie)							
	e of References Cited (PTO-892)	4) 🔲 Interview Sur	nmary (PTO-413)					
2) Notic	e of Draftsperson's Patent Drawing Review (Paper No(s)/l	Paper No(s)/Mail Date 5) Notice of Informal Patent Application (PTO-152)				
	mation Disclosure Statement(s) (PTO-1449 o r No(s)/Mail Date <u>12/19/05</u> .	6) Other:		J 102)				

Art Unit: 3736

DETAILED ACTION

Information Disclosure Statement

The information disclosure statement filed 12/19/05 complies with the provisions of 37 CFR 1.97, 1.98 and MPEP § 609. It has been placed in the application file, and the information referred to therein has been considered by the examiner as to the merits.

Claim Rejections - 35 USC § 103


- The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness 1. rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- Claims 72 76 are rejected under 35 U.S.C. 103(a) as being unpatentable over WO 2. 01/53792 A2 to Given Imaging Ltd. in view of U.S. Patent No. 6,330,464 to Colvin, Jr. et al.

In regards to claims 72 – 76, Given Imaging Ltd. discloses a method for determining body lumen conditions including: receiving an endo-luminal sample on an interaction surface (54), the surface includes an indicator for reacting with an endo-luminal sample (Page 11, line 32 - Page 12, line 2), the imager and interaction surface are considered to be positioned behind an optical window in that the optical window (53) extends to the left of both the interaction surface (52) and the imager (55) (Figures 7 and 8). Given Imaging Ltd. discloses illuminating the interaction surface and imaging optical changes in the interaction surface with an optical system (Page 11, line 29 - Page 12, line 3). The interaction surface is transparent in the wavelength of illumination (Page 11, line 30). Given Imaging Ltd. discloses transmitting the video signals and a receiving system for receiving the video signals (Page 11, line 26). However, Given Imaging Ltd fails to disclose the interaction surface being Art Unit: 3736

an interaction chamber. Colvin, Jr. et al. discloses an autonomous device for determining in vivo condition. Colvin, Jr. et al. teaches the device having an indicator located within an interaction chamber. Each chamber is sealed by a membrane which selectively enables passage of a sample but not of the indicator (Col. 6, lines 51 - 56). It would have been obvious to one having ordinary skill in the art at the time the invention was made to modify the interaction surface as disclosed by Given Imaging Ltd. to include an interaction chamber as taught by Colvin, Jr. et al. in order to help protect the indictor while in use (Col. 25, lines 50 - 61).

Response to Arguments

3. Applicant's arguments filed 11/17/05 have been fully considered but they are not persuasive. Applicant asserts that no reasonable interpretation of "behind an optical window" could refer to a reactant placed on the outside of the window as in the case with Colvin, Jr. et al. However, the Examiner disagrees. Applicant's claim does not require the interaction chamber to be positioned within the confines of the body of the capsule, merely "behind an optical window". In this regard, the Examiner has reasonably interpreted "behind" as being "toward the back of" (Merriam-Webster's Collegiate Dictionary, 10th ed.). As stated previously, the imager and interaction surface are considered to be positioned behind an optical window in that the optical window (53) extends to the left of both the interaction surface (52) and the imager (55).



Application/Control Number: 10/046,540 Page 4

Art Unit: 3736

As can be clearly seen in the above figure, the optical window is located at the front of the capsule, the power source (57) is located at the back of the capsule and the interaction surface is positioned "behind" the front and ahead of the back.

Conclusion

4. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jonathan ML Foreman whose telephone number is (571)272-4724. The examiner can normally be reached on Monday - Friday 8:00 am - 4:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Max Hindenburg can be reached on (571)272-4726. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/046,540

Art Unit: 3736

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

IMLF

MAX F. HINDENBURG SUPERVISORY PATENT EXAMINER TECKNOLOGY CENTER 3700

Page 5